Abstract
To evaluate pre and post-operative spirometry in patients with tuberculosis sequelae undergoing lobectomy. We selected 20 patients, aged between 15 and 56 years, of both genders, with a history of tuberculosis treatment, with repeated infections or hemoptysis and indication of pulmonary lobectomy. The tuberculosis treatment time was six months, and onset of symptoms, between one and 32. We evaluated and compared vital capacity (VC), forced vital capacity (FVC), forced expiratory volume (FEV1), the FEV1/FVC, forced expiratory flow (FEF) and peak expiratory flow (PEF) preoperatively and after the first, third and sixth postoperative months (POM). The significance level (á) used in all tests was 5%, ie, it was considered significant when p <0.05. The averages found were: Vital Capacity (VC) - Preoperative: 2.83; 1st POM: 2.12; 3rd POM: 2.31; 6th POM: 2.43. Forced Vital Capacity (FVC) - Preoperative: 2.97; 1st POM: 2.21; 3rd POM: 2.35; 6th POM: 2.53. Expiratory Volume in 1 second (FEV1) - Preoperative: 2.23; 1st POM: 1.75; 3rd POM: 1.81; 6th POM 1.97. There was marked decrease in lung function in the first month after surgery, but there was an improvement of the parameters from the third month, with gradual increase up to the sixth month. There was no recovery of preoperative spirometric parameters at six months postoperatively in patients with sequelae of tuberculosis submitted to lobectomy.
Highlights
Tuberculosis (TB) caused by Mycobacterium tuberculosis, or M. tuberculosis, is still common in countries like Brazil[1]
Tuberculosis is perhaps the oldest disease known to mankind, with records of injuries found in vertebrae of mummies from about four thousand years ago[1,5,6,7,8,9,10]
We selected 20 patients, ten men and ten women, with a previous history of TB treatment who had symptomatic sequelae, ie, recurrent infection or hemoptysis, Work performed at the University Hospital of the Federal University of Maranhão at Presidente Dutra, Maranhao State, Brazil
Summary
Tuberculosis (TB) caused by Mycobacterium tuberculosis, or M. tuberculosis, is still common in countries like Brazil[1]. It reaches the 21st century as a public health problem and remains unsolved, with significant morbidity and mortality[2]. It is the most common infectious disease in humans[3], killing nearly three million people worldwide each year[4]. Tuberculosis is perhaps the oldest disease known to mankind, with records of injuries found in vertebrae of mummies from about four thousand years ago[1,5,6,7,8,9,10]. The specific treatment, initiated in 1944 with the discovery of streptomycin, followed in 1952 with isoniazid[11,12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call